|
**Overview**: Lupus Anticoagulant DRVVT Panel**Introduction**: The Lupus Anticoagulant DRVVT Panel is a diagnostic tool designed to screen for lupus anticoagulant using plasma samples. In India, antiphospholipid syndrome (APS) affects ~1-5 percent of women with recurrent miscarriage/thrombosis, and lupus anticoagulant (LA) is a key criterion, associated with arterial/venous thrombosis and obstetric complications. High morbidity from under-testing in rural/low-SES women with recurrent abortions or young patients with stroke/DVT, limited coagulation labs, delayed anticoagulation leading to recurrent events or fetal loss. Per hematology practices aligned with ICMR and Indian Society of Haematology & Blood Transfusion guidelines, the test employs immunoassay for DRVVT screen, DRVVT confirm, APTT, and LA ratio over 1-2 days with high accuracy, valuable for confirming LA in suspected APS. This diagnostic falls under coagulation screening and targets patients with thrombosis, miscarriage, or SLE, addressing accurate detection to guide lifelong anticoagulation or low-dose aspirin. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise LA identification and reducing thrombotic/obstetric burden. Its plasma-based approach ensures reliable functional assay.**Other Names**: LAC DRVVT Pnl.**FDA Status**: FDA approved, CLIA certified for hematology/immunology, compliant with 2025 standards.**Historical Milestone**: DRVVT-based LA testing standard; in India, used in thrombosis clinics.**Purpose**: The test assesses 4 parameters including DRVVT screen to guide lupus anticoagulant screening, confirm presence, inform anticoagulation.**Test Parameters**: 1. DRVVT Screen, 2. DRVVT Confirm, 3. APTT, 4. Lupus Anticoagulant Ratio.**Pretest Condition**: No fasting required; patients should have thrombosis or miscarriage history.**Specimen**: 3 mL plasma in NaCit tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve coagulation factors, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on thrombosis, miscarriage, SLE.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undetected LA including recurrent thrombosis, benefits of screening, and minimal discomfort from sampling.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or anticoagulants can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Prolonged DRVVT with confirm indicates LA, necessitating specialist input.**Specialist Consultation**: Hematologists/rheumatologists should be consulted for management.**Additional Supporting Tests**: Anti-cardiolipin, anti-beta2GP for confirmation.**Test Limitations**: Affected by anticoagulants; comprehensive approach required.**References**: Indian Journal of Hematology 2024, Thrombosis Studies India 2023. |
